KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.98

Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small cell lung cancer: patient-reported outcomes in the RATIONALE-315 trial.

Dongsheng Yue, Federico Cappuzzo, Wenxiang Wang, Hongxu Liu, Qixun Chen, Shengfei Wang, Shiang Jiin Leaw, Bin Yao, Frederick B Barnes, Gisoo Barnes, Changli Wang

Future Oncol 22(24) 2911-2921

PMID42990047
PMCIDPMC13757690
DOI10.1080/14796694.2026.2743385
发表日期2026-11-06
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
摘要

摘要

INTRODUCTION: In the phase III RATIONALE-315 trial (NCT04379635), perioperative tislelizumab plus neoadjuvant chemotherapy significantly improved overall and event-free survival versus placebo plus chemotherapy in patients with resectable stage II-IIIA non-small cell lung cancer (NSCLC). Here, report prespecified patient-reported outcomes (PROs). METHODS: PROs were evaluated using the EORTC QLQ-C30 and QLQ-LC13 questionnaires. A mixed-effects model for repeated measures was used for PRO endpoints at neoadjuvant Cycle 3 and adjuvant Cycles 3, 5, and 7. Time to deterioration (TTD) was also analyzed. RESULTS: 453 patients were randomized to tislelizumab (n = 226) or placebo (n = 227). At adjuvant Cycles 3 and 5, chest pain was maintained with tislelizumab versus worsening with placebo (LSM difference -4.99 [95% CI: -9.06 to -0.93]; p = 0.016) and -4.15 [95% CI: -7.86 to -0.44]; p = 0.028, respectively). At adjuvant Cycle 7, greater improvement in coughing was observed in the tislelizumab arm versus placebo (-5.10 [95% CI: -9.79 to -0.40]; p = 0.034). TTD analysis showed a lower risk of chest pain with tislelizumab (HR 0.58; p = 0.004). CONCLUSION: Perioperative tislelizumab improved coughing and chest pain compared with placebo in patients with resectable NSCLC. These data provide additional support of this regimen in this patient population. CLINICAL TRIAL REGISTRATION: www.clinicaltrials.gov identifier is NCT04379635.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。